Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kitamura

Showing results (1241-1250 of 1,248) with videos related to

Pageof 125
Sort By:
You have reached the last page of results.This site can display upto 1,248 results.
American Journal of Human Genetics|August 1, 1996
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of diseaseM H Ruttledge, A A Andermann, C M Phelan, et al.
The Japanese Journal of Antibiotics|December 1, 1996
[Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders]K Kitamura, K Miyagawa, A Urabe, et al.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|September 24, 1998
[Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ]K Kitamura, H Hirai, N Hosoya, et al.
The Japanese Journal of Antibiotics|April 29, 2000
[Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases]A Urabe, A Fujita, K Aoki, et al.
The ISME Journal|November 14, 2020
Plant part and a steep environmental gradient predict plant microbial composition in a tropical watershedJared Bernard, Christopher B Wall, Maria S Costantini, et al.
Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.
Blood|May 1, 1997
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cellsG Q Chen, X G Shi, W Tang, et al.
Leukemia|February 4, 2014
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patientsR Kihara, Y Nagata, H Kiyoi, et al.
Pageof 125

Showing results (1241-1250 of 1,248) with videos related to

Sort By:
Pageof 125
You have reached the last page of results.This site can display upto 1,248 results.
American Journal of Human Genetics|August 1, 1996
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of diseaseM H Ruttledge, A A Andermann, C M Phelan, et al.
The Japanese Journal of Antibiotics|December 1, 1996
[Clinical study on a concomitant therapy with fluconazole and human recombinant granulocyte colony stimulating factor in the treatment of systemic fungal infections with hematological disorders]K Kitamura, K Miyagawa, A Urabe, et al.
Kansenshogaku Zasshi. the Journal of the Japanese Association for Infectious Diseases|September 24, 1998
[Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ]K Kitamura, H Hirai, N Hosoya, et al.
The Japanese Journal of Antibiotics|April 29, 2000
[Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases]A Urabe, A Fujita, K Aoki, et al.
The ISME Journal|November 14, 2020
Plant part and a steep environmental gradient predict plant microbial composition in a tropical watershedJared Bernard, Christopher B Wall, Maria S Costantini, et al.
Cancer Research|June 24, 2000
Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumorsA M Scott, D Geleick, M Rubira, et al.
Blood|May 1, 1997
Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cellsG Q Chen, X G Shi, W Tang, et al.
Leukemia|February 4, 2014
Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patientsR Kihara, Y Nagata, H Kiyoi, et al.
Pageof 125